drugset
drugset / Trial / NCT02497716

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

NCT02497716 ↗

Phase 1 Completed 47 enrolled Bayer Janssen Research & Development, LLC · collab
NaSingle-groupOpen-labelOther

Summary

To characterize the pharmacokinetic profile of rivaroxaban administered as granules for suspension formulation and to document safety and tolerability

Timeline

Start
2015-11-04
Primary completion
2018-05-22
Completion
2018-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified — Oral

Indications

thrombotic disease